Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.420-4.510 for the period, compared to the consensus estimate of 4.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $45.95 on Friday. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $2.17 billion, a PE ratio of 11.75, a P/E/G ratio of 1.55 and a beta of 0.40. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $89.37. The company has a 50-day moving average price of $58.32 and a two-hundred day moving average price of $61.49.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to the consensus estimate of $291.99 million. Prestige Consumer Healthcare had a return on equity of 11.62% and a net margin of 17.48%.Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts forecast that Prestige Consumer Healthcare will post 4.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PBH shares. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $74.75.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of PBH. UMB Bank n.a. raised its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares in the last quarter. Danske Bank A S purchased a new stake in Prestige Consumer Healthcare in the third quarter valued at approximately $37,000. Brown Brothers Harriman & Co. purchased a new stake in Prestige Consumer Healthcare in the third quarter valued at approximately $44,000. Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Prestige Consumer Healthcare by 142.8% in the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after purchasing an additional 647 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).